Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
E-pub ahead of print

Ticagrelor and The Risk of Staphylococcus Aureus Bacteremia and Other Infections

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Patient-Reported Outcomes and Medication Adherence in Patients with Heart Failure

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Assessing absolute stroke risk in patients with atrial fibrillation using a risk factor based approach

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Vitamin K antagonists vs. direct oral anticoagulants after transcatheter aortic valve implantation in atrial fibrillation

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Switching from Vitamin K Antagonist to Dabigatran in Atrial Fibrillation: Differences According to Dose

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Intensive blood pressure lowering in different age categories: insights from the Systolic Blood Pressure Intervention Trial

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Capsid-like particles decorated with the SARS-CoV-2 receptor-binding domain elicit strong virus neutralization activity

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Clopidogrel, prasugrel, and ticagrelor for all-comers with ST-segment elevation myocardial infarction

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Nationwide cardiovascular disease admission rates during a second COVID-19 lockdown

    Publikation: Bidrag til tidsskriftLetterForskningpeer review

  4. Workforce Attachment after Ischemic Stroke – The Importance of Time to Thrombolytic Therapy

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Day-to-day measurement of physical activity and risk of atrial fibrillation

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

AIM: To investigate the 1-year risks of Staphylococcus aureus bacteremia (SAB), sepsis, and pneumonia in patients who underwent percutaneous coronary intervention and were treated with ticagrelor versus clopidogrel.

METHODS AND RESULTS: In this nationwide observational cohort study, 26,606 patients who underwent urgent or emergent percutaneous coronary intervention (January 2011-December 2017) and initiated treatment with ticagrelor (N = 20,073 [75.5%]; median age 64 years [25th-75th percentile 55-72 years]; 74.8% men) or clopidogrel (N = 6,533 [24.5%]; median age 68 years [25th-75th percentile 58-77 years]; 70.2% men) were identified using Danish nationwide registries. The 1-year standardized absolute risks of outcomes was calculated based on cause-specific Cox regression models, and average treatment effects between treatment groups were obtained as standardized differences in absolute 1-year risks. The absolute 1-year risk of SAB was 0.10% [95% CI, 0.05% to 0.15%] in the ticagrelor group and 0.29% [95% CI, 0.17% to 0.42%] in the clopidogrel group. Compared with clopidogrel, treatment with ticagrelor was associated with a significantly lower absolute 1-year risk of SAB (absolute risk difference -0.19% [95% CI, -0.32% to -0.05%], p-value 0.006). Likewise, treatment with ticagrelor was associated with a significantly lower absolute 1-year risk of sepsis (0.99% [95% CI, 0.83% to 1.14% versus 1.49% [95%CI, 1.17% to 1.80%]; absolute risk difference -0.50% [95% CI, -0.86% to -0.14%], p-value 0.007) and pneumonia (3.13% [95%CI, 2.86% to 3.39% versus 4.56% [95%CI, 4.03% to 5.08%]; absolute risk difference -1.43% [95% CI, -2.03% to -0.82%], p-value < 0.001) compared with clopidogrel.

CONCLUSIONS: Treatment with ticagrelor was associated with a significantly lower 1-year risk of SAB, sepsis, and pneumonia compared with clopidogrel.

OriginalsprogEngelsk
TidsskriftEuropean heart journal. Cardiovascular pharmacotherapy
ISSN2055-6837
DOI
StatusE-pub ahead of print - 2021

Bibliografisk note

© Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2020. For permissions, please email: journals.permissions@oup.com.

ID: 60682489